Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.3389/FPHYS.2017.00982 | ||||
| Año | 2017 | ||||
| Tipo | revisión |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Lysosomal storage disorders (LSD) are characterized by the accumulation of diverse lipid species in lysosomes. Niemann-Pick type NB (NPA/B) and type C diseases Niemann-Pick type C (NPC) are progressive LSD caused by loss of function of distinct lysosomal-residing proteins, acid sphingomyelinase and NPC1, respectively. While the primary cause of these diseases differs, both share common biochemical features, including the accumulation of sphingolipids and cholesterol, predominantly in endolysosomes. Besides these alterations in lysosomal homeostasis and function due to accumulation of specific lipid species, the lysosomal functional defects can have far-reaching consequences, disrupting intracellular trafficking of sterols, lipids and calcium through membrane contact sites (MCS) of apposed compartments. Although MCS between endoplasmic reticulum and mitochondria have been well studied and characterized in different contexts, emerging evidence indicates that lysosomes also exhibit close proximity with mitochondria, which translates in their mutual functional regulation. Indeed, as best illustrated in NPC disease, alterations in the lysosomal-mitochondrial liaisons underlie the secondary accumulation of specific lipids, such as cholesterol in mitochondria, resulting in mitochondrial dysfunction and defective antioxidant defense, which contribute to disease progression. Thus, a better understanding of the lysosomal and mitochondrial interactions and trafficking may identify novel targets for the treatment of Niemann-Pick disease.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Torres, Sandra | Mujer |
CSIC - España
Inst Invest Biomed August Pi & Sunyer - España Consejo Superior de Investigaciones Científicas - España Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas - España Universitat de Barcelona - España |
| 2 | BALBOA-CASTILLO, ELISA IVANA | Mujer |
Pontificia Universidad Católica de Chile - Chile
Facultad de Medicina - Chile |
| 3 | ZANLUNGO-MATSUHIRO, SILVANA | Mujer |
Pontificia Universidad Católica de Chile - Chile
Facultad de Medicina - Chile |
| 4 | Enrich, Carlos | Hombre |
Univ Barcelona - España
Universitat de Barcelona - España Universitat de Barcelona, Facultad de Medicina y Ciencias de la Salud - España |
| 5 | Garcia-Ruiz, Carmen | Mujer |
CSIC - España
Inst Invest Biomed August Pi & Sunyer - España Southern Calif Res Ctr ALDP & Cirrhosis - Estados Unidos Consejo Superior de Investigaciones Científicas - España Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas - España Southern California Research Center for ALPD and Cirrhosis - Estados Unidos Universitat de Barcelona - España |
| 6 | Fernandez-Checa, Jose C. | Hombre |
CSIC - España
Inst Invest Biomed August Pi & Sunyer - España Southern Calif Res Ctr ALDP & Cirrhosis - Estados Unidos Consejo Superior de Investigaciones Científicas - España Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas - España Southern California Research Center for ALPD and Cirrhosis - Estados Unidos Universitat de Barcelona - España |
| Fuente |
|---|
| National Institutes of Health |
| Generalitat de Catalunya |
| Instituto de Salud Carlos III |
| National Institute on Alcohol Abuse and Alcoholism |
| Agència de Gestió d'Ajuts Universitaris i de Recerca |
| Fundacio La Marato de TV3 |
| Plan Nacional de I+D |
| Fundacio Marato de TV3, La Mutua Madrilena grant from the Institute Salud Carlos III |
| Plan Nacional de I+D, Spain |
| AGAUR of the Generalitat de Catalunya |
| Research Center for Liver and Pancretic Diseases |
| CIBEREHD |
| NIAAA/NIH |
| META |
| AGAUR of the |
| La Mutua Madrilena |
| Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas |
| Agradecimiento |
|---|
| The work was supported by grants SAF-2014-57674-R, SAF-2015-69944-R from Plan Nacional de I+D, Spain, Fundacio Marato de TV3, La Mutua Madrilena, P111/0325 (META) grant from the Institute Salud Carlos III, and by the support of CIBEREHD; the center grant P50-AA-11999 Research Center for Liver and Pancretic Diseases funded by NIAAA/N111; and support from AGAUR of the Generalitat de Catalunya 2014-SGR785. |
| The work was supported by grants SAF-2014-57674-R, SAF-2015-69944-R from Plan Nacional de I+D, Spain, Fundació Marató de TV3, La Mutua Madrileña, PI11/0325 (META) grant from the Instituto Salud Carlos III, and by the support of CIBEREHD; the center grant P50-AA-11999 Research Center for Liver and Pancretic Diseases funded by NIAAA/NIH; and support from AGAUR of the Generalitat de Catalunya 2014-SGR785. |